Clinical Trial

A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

Study acronym: CONOR
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Data from niraparib treatment is not available in real-world setting in Latin America. The present study aims to collect data from patients treated with niraparib within the Latin America Expanded Access Program (EAP) in clinical practice in Brazil and Argentina and who meet the eligibility criteria for this study, without additional intervention.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-04; most recent amendment 2025-02-11.
Status change: Recruiting → Active, Not Recruiting 2025-02-11
Status change: Not Yet Recruiting → Recruiting 2023-08-18
Trial Details
NCT Number NCT05857397
Lead Sponsor Latin American Cooperative Oncology Group
Collaborators: GlaxoSmithKline
Conditions Ovarian Cancer
Enrollment 64 participants
Start Date 2023-07-21
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-12